After nearly two years as the signature on the numbers, and now the title to match. David House has been promoted to Chief Financial Officer of Armata Pharmaceuticals, and a Los Angeles clinical-stage biotechnology company taking on antimicrobial resistance, one of the most urgent threats to global public health.
Effective July 17, 2026, David was promoted from Senior Vice President, Finance, the role he held since August 2024, to Chief Financial Officer, reporting directly to Chief Executive Officer Dr. Deborah Birx, M.D.
David brings very relevant experience to Armata. Before joining the Company, David served as Corporate Controller and Vice President of Accounting at ZO Skin Health, an international, medical-grade skincare brand owned by Blackstone, where he led global accounting operations and played a central role in the company’s acquisition by one of the largest private equity firms in the world. Earlier, he spent four years at Peregrine Pharmaceuticals and its wholly owned subsidiary and contract manufacturer, Avid Bioservices, during the final stretch of an FDA approval push, establishing the processes, procedures, and revenue recognition framework largely from the ground up. That was a valuable rehearsal for the work that needs to be done at Armata.
His range is deliberately broad: treasury, FP&A, domestic and international accounting operations, multi-currency consolidations, technical accounting, and ERP implementations. At Peregrine and Avid, he served as Controller, implementing ASC 606 and taking the lead on technical accounting while leading the accounting function. He began his career with three and a half years in public accounting as a Senior Auditor at Windes and holds a Bachelor of Arts in Business Administration with an accounting concentration from California State University, Fullerton. David is an Orange County native who established his public-company finance career one hard audit at a time.
The most valuable appointments are not necessarily the “flashy” outside hires. They are the internal elevations, the moment a board looks at the person who has quietly been holding the weight and says, officially, we trust you with more. For a clinical-stage biotech, that continuity is not just “a nice-to-have”. It is oxygen.
Armata is entering an exciting chapter. The late clinical-stage company is focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections. AP-SA02, its Staphylococcus aureus phage product candidate, is advancing toward a pivotal Phase 3 superiority study that is anticipated to initiate in the second half of 2026. When a company advances from early-stage clinical trials into a registrational study, the finance function is more than back office, it becomes a strategic function. Financing decisions and appropriate deployment of cash are important in determining if a company has the resources to ultimately make its products available to patients. During this period, the person holding CFO title must have the complete trust of management and the board.
The timing is consistent with a broader trend. With CFO turnover at a seven-year high, the companies winning are the ones that built the bench before they needed it. This is what Armata is doing. It is the same discipline we track across the SoCal talent market: very often the leaders who get elevated are the ones already operating a level above their title long before they join the C-suite. Competence compounds and trust follows. The promotion is just the paperwork catching up to a decision that the work already made.
To David House: congratulations. The title finally matches the standard you have been setting all along, and the most exciting chapter looks like the one you just started.
“I have had the privilege of helping to build Armata’s financial foundation over the past two years. The Company is now at an exciting point in its evolution with our lead product advancing toward Phase 3 clinical development in an area of major unmet medical need. My focus will be to ensure we have the financial discipline, resources, and execution required to move our cutting-edge science through the clinic and ultimately to patients.”
David House, Chief Financial Officer, Armata Pharmaceuticals
Know a leader who deserves this spotlight?
This is what we do at Recruiter Hustle: we don’t just report the move, we honor the person behind it. If you, your company, or someone you admire just stepped into a new chapter, we want to tell that story right.
→ Submit a People Move • or reach out to Cathy Trinh directly, and let’s put your name in the light.
HEART. HUMAN. HUSTLE.
Sources & verification
Appointment: Armata Pharmaceuticals Current Report on Form 8-K, promotion to Chief Financial Officer effective July 17, 2026; company management disclosures and SEC proxy filings. Career background and quotes confirmed directly by Armata Pharmaceuticals and reviewed by company Legal prior to publication.
Chief Talent Strategist & Editor-in-Chief | 26-year global recruiting veteran, #1 bestselling author, cancer survivor & humanitarian. Founder of Recruiter Hustle, OC/LA's no-filter media platform for talent, finance & recruiting professionals. Heart. Human. Hustle.